9 recruiting, 7 completed, 4 withdrawn, 2 active not recruiting. 25 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 25 | Recruiting 9, Completed 7, Withdrawn 4, Active not recruiting 2, Terminated 2, Unknown 1 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) [18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer | Early Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2027-06-01 | 2026-08-17 |
| Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC RYZ211/212 - Metastatic Urothelial Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | RayzeBio, Inc. | 40 | 2026-06-15 | 2026-10-13 |
| A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors PBA-0111 - Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult | Early Phase 1 | Recruiting | Pure Biologics S.A. | 12 | 2025-03-27 | 2025-08-11 |
| Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer Dupilumab, Pembrolizumab, Paclitaxel - Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Early Phase 1 | Recruiting | Rima Patel | 15 | 2025-03-05 | 2026-05-14 |
| Neratinib in Combination With Ruxolitinib in Patients With mTNBC Neratinib Oral Tablet, Ruxolitinib Oral Tablet - Metastatic Triple-Negative Breast Carcinoma, Breast Cancer | Early Phase 1 | Recruiting | Baylor Research Institute | 20 | 2024-09-16 | 2026-10-13 |
| Breast Cancer PSMA PET PET imaging - Triple Negative Breast Cancer | Early Phase 1 | Recruiting | Ahmad Shariftabrizi | 30 | 2024-08-29 | 2026-08-06 |
| Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) Cyclosporin A - Triple Negative Breast Cancer, DNA Damage Repair Deficiency | Early Phase 1 | Withdrawn | Virginia G. Kaklamani | 2024-07-01 | 2025-07-16 | |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy Leukapheresis, Dendritic Cell (DC) Vaccine - Breast Cancer, Triple Negative Breast Cancer | Early Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 16 | 2024-06-12 | 2026-04-01 |
| 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors 177Lu-RAD204 - PDL1 Gene Mutation, Non Small Cell Lung Cancer | Early Phase 1 | Recruiting | Radiopharm Theranostics, Ltd | 30 | 2024-06-03 | 2026-02-19 |
| A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors PBA-0405 - Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult | Early Phase 1 | Completed | Pure Biologics S.A. | 8 | 2024-04-29 | 2025-08-11 |
| Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection - Breast Cancer, Locally Advanced Breast Cancer | Early Phase 1 | Recruiting | Alison Stopeck | 30 | 2024-03-06 | 2026-01-15 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism quercetin, EGCG, metformin , zinc - Breast Cancer Female, Triple Negative Breast Cancer | Early Phase 1 | Unknown | Ministry of Health, Saudi Arabia | 200 | 2023-01-01 | 2023-01-11 |
| CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational - Breast Cancer, Early-Onset | Early Phase 1 | Active not recruiting | Rutgers, The State University of New Jersey | 34 | 2022-04-06 | 2026-02-09 |
| Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer α-lactalbumin vaccine, Zymosan - Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Early Phase 1 | Completed | George T. Budd | 35 | 2021-10-01 | 2026-07-17 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer Atezolizumab, Cryosurgery, Nab-paclitaxel - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Early Phase 1 | Withdrawn | Mayo Clinic | 2020-01-23 | 2023-01-06 | |
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer Pelareorep, Letrozole, Atezolizumab - Breast Cancer | Early Phase 1 | Terminated | Oncolytics Biotech | 26 | 2019-03-29 | 2022-08-15 |
| Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Biopsy, Chemokine Modulation Therapy, Celecoxib - Triple -Negative Breast Cancer, Estrogen Receptor Negative | Early Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2019-01-09 | 2023-07-18 |
| Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Entinostat - Breast Cancer, Invasive Breast Cancer | Early Phase 1 | Terminated | UNC Lineberger Comprehensive Cancer Center | 5 | 2018-11-28 | 2024-03-25 |
| Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer Glembatumumab Vedotin - Triple Negative Breast Cancer | Early Phase 1 | Withdrawn | University of Virginia | 2018-05-01 | 2024-12-09 |
Showing 20 of 25. Sign in to see all of them.
Breast Neoplasms (13) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Inflammatory Breast Neoplasms (1) · Melanoma (1) · Neoplasm, Residual (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Turcot syndrome (1)
Breast Diseases (25) · Neoplasms (25) · Neoplasms by Site (25) · Skin Diseases (25) · Skin and Connective Tissue Diseases (25) · Breast Neoplasms (12) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
pembrolizumab (3) · atezolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Benzenesulfonamides (1) · Biopsy (1) · CPG-oligonucleotide (1) · Carboplatin (1) · Celecoxib (1) · Cryosurgery (1) · Cyclosporine (1) · Enzyme-Linked Immunosorbent Assay (1) · Flow Cytometry (1) · Immunoenzyme Techniques (1) · Immunologic Techniques (1)
Mayo Clinic (2) · Pure Biologics S.A. (2) · UNC Lineberger Comprehensive Cancer Center (2) · Ahmad Shariftabrizi (1) · Alison Stopeck (1) · Baylor Research Institute (1) · George T. Budd (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Joseph Baar, MD, PhD (1) · M.D. Anderson Cancer Center (1) · Ministry of Health, Saudi Arabia (1) · OHSU Knight Cancer Institute (1) · Oncolytics Biotech (1) · Radiopharm Theranostics, Ltd (1) · RayzeBio, Inc. (1)
United States (17) · Australia (2) · Belgium (1) · New Zealand (1) · South Africa (1) · Spain (1)
Lisa Carey, MD (2) · Alison Stopeck, MD (1) · Ann Smeets, Prof. Dr. (1) · Barbara A Pockai, M.D. (1) · Edith A Perez, M.D. (1) · Emmanuel M Gabriel (1) · Evthokia Hobbs, M.D. (1) · Freddy Escorcia (1) · Gaiane M Rauch (1) · George T Budd, MD (1) · Hatem Soliman, MD (1) · Heying Duan (1) · Janis O'Malley, MD (1) · John Weinberg (1) · John Weinberg, MBBCH (1)
P30CA015083 (1), P30CA016672 (1), P50CA058223 (1)